Jonathan Zalevsky Sells 186 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 186 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $13,388.28. Following the completion of the transaction, the insider owned 9,570 shares of the company’s stock, valued at $688,848.60. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, June 30th, Jonathan Zalevsky sold 5,681 shares of Nektar Therapeutics stock. The shares were sold at an average price of $70.00, for a total transaction of $397,670.00.
• On Monday, June 15th, Jonathan Zalevsky sold 5,538 shares of Nektar Therapeutics stock. The shares were sold at an average price of $60.71, for a total transaction of $336,211.98.

Nektar Therapeutics Stock Performance

NKTR stock opened at $74.02 on Friday. Nektar Therapeutics has a one year low of $26.45 and a one year high of $109.00. The company’s fifty day moving average price is $69.63 and its 200-day moving average price is $70.36. The company has a market capitalization of $2.53 billion, a PE ratio of -11.05 and a beta of 1.14.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.97) by $0.74. The company had revenue of $10.13 million during the quarter, compared to analysts’ expectations of $10.43 million. Nektar Therapeutics had a negative net margin of 287.84% and a negative return on equity of 37.87%. On average, research analysts predict that Nektar Therapeutics will post -8.6 EPS for the current fiscal year.

Nektar Therapeutics News Summary

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Nektar’s latest quarterly results included an adjusted loss of $1.23 per share, substantially better than the $1.97 analyst consensus. The earnings-call transcript provides additional management commentary on the company’s pipeline and financial outlook. Nektar Q2 2026 Earnings Call Transcript
• Positive Sentiment: Institutional ownership remains high at approximately 75.9%, while several funds—including AQR Capital Management, Two Seas Capital and Armistice Capital—recently increased their positions. The broader analyst consensus is still “Moderate Buy,” with an average price target well above the current trading level. Nektar institutional ownership and analyst ratings
• Neutral Sentiment: JPMorgan initiated coverage with a “Neutral” rating and a $65 price target. The target is below the recent share price, signaling limited near-term upside in JPMorgan’s view, although the rating is not an outright sell recommendation. JPMorgan initiates coverage of Nektar
• Neutral Sentiment: CEO Howard Robin and insider Jonathan Zalevsky sold shares to cover tax withholding obligations tied to vested equity awards. The transactions were relatively small compared with their remaining holdings, reducing their significance as a bearish signal. Nektar insider transactions
• Negative Sentiment: Revenue of $10.13 million fell slightly short of the $10.43 million estimate, while Nektar continues to report substantial losses and is expected to post approximately negative $8.60 in full-year EPS. HC Wainwright also issued a negative outlook for NKTR earnings, adding to concerns about ongoing cash burn and execution risk. HC Wainwright earnings outlook

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nektar Therapeutics in a research report on Tuesday, June 2nd. Piper Sandler boosted their target price on Nektar Therapeutics from $105.00 to $192.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wall Street Zen raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, May 17th. Canaccord Genuity Group assumed coverage on Nektar Therapeutics in a report on Wednesday, July 22nd. They set a “buy” rating and a $153.00 price target for the company. Finally, Wedbush cut their price target on Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, May 11th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Nektar Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $141.50.

Hedge Funds Weigh In On Nektar Therapeutics

Institutional investors have recently bought and sold shares of the business. Braidwell LP lifted its position in Nektar Therapeutics by 112.7% during the second quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after purchasing an additional 250,916 shares during the last quarter. Pale Fire Capital SE bought a new stake in shares of Nektar Therapeutics in the 2nd quarter worth about $234,000. Wellington Management Group LLP bought a new stake in shares of Nektar Therapeutics in the 2nd quarter worth about $802,000. AWM Investment Company Inc. purchased a new stake in shares of Nektar Therapeutics during the 2nd quarter valued at about $1,461,000. Finally, Great Lakes Advisors LLC purchased a new stake in shares of Nektar Therapeutics during the 2nd quarter valued at about $206,000. Institutional investors own 75.88% of the company’s stock.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.